Compare Illumina, Inc. (ILMN) vs Intel Corp (INTC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Intel Corp — how do they compare? Illumina, Inc. trades at $193.06 (market cap $28.96B), while Intel Corp trades at $99.42 (market cap $491.89B). The key difference: Intel Corp is far larger — about 17× Illumina, Inc.'s market cap, and Intel Corp pays a 2.24% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | INTC | |
|---|---|---|
Market Cap | $28.96B | $491.89B |
Sector | Health | Technology |
52-Week High | $205.10 | $140.94 |
52-Week Low | $91.00 | $21.81 |
Enterprise Value | $30.32B | $512.70B |
Volume | — | 43,552,012 |
Dividend Yield | — | 2.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $187.96, down 2.97% on the day, but maintains strong fundamental momentum with three consecutive quarterly earnings beats. The stock shows robust profitability with 66.38% gross margins and 18.34% net income margins, though technical indicators suggest near-term bearish pressure. Recent institutional buying activity and positive analyst coverage (51% buy ratings) support the stock's long-term growth narrative in the genomics sector.
The outlook remains positive with a consensus price target of $201.58 representing 7% upside potential. Key catalysts include continued NovaSeq X adoption and AI partnerships, while risks involve competitive pressures and execution challenges in achieving projected revenue growth. The company's turnaround from net losses to $850M profit in 2025 demonstrates improved operational efficiency.
Intel (INTC) trades at $101.65, up 1.84% on the day, with a bullish technical signal from moving averages but a neutral oscillator stance. The company reported a net loss of $267 million in 2025 despite revenue of $52.85 billion, though it beat EPS estimates in recent quarters. Recent news highlights a $20 billion stock offering to fund AI expansion, causing short-term volatility but viewed as strategic for long-term growth.
Outlook is mixed: analyst consensus price target of $116.67 suggests upside, supported by AI investments, but high P/E of 904.17 and negative profit margins pose valuation risks. Key risks include intense competition, execution challenges in foundry growth, and reliance on capital raises amid cash burn in strategic segments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Intel Corp
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →
